Neurocrine Biosciences Inc NBIX:NASDAQ

Last Price$80.79NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/01/21

Today's Change-2.46(2.95%)
Bid (Size)$78.88 (1)
Ask (Size)$83.91 (1)
Day Low / High$79.89 - 85.45
Volume983.4 K
 

View Biotechnology IndustryPeer Comparison as of 12/01/2021

 

Neurocrine Biosciences Inc ( NASDAQ )

Price: $80.79
Change: -2.46 (2.95%)
Volume: 983.4 K
4:00PM ET 12/01/2021
 
 

Mirati Therapeutics Inc ( NASDAQ )

Price: $132.04
Change: -4.73 (3.46%)
Volume: 483.2 K
4:00PM ET 12/01/2021
 
 

Arrowhead Pharmaceuticals Inc ( NASDAQ )

Price: $67.00
Change: -3.05 (4.35%)
Volume: 700.0 K
4:00PM ET 12/01/2021
 
 

Intellia Therapeutics Inc ( NASDAQ )

Price: $106.92
Change: -8.09 (7.03%)
Volume: 26.00
4:00PM ET 12/01/2021
 
 

Natera Inc ( NASDAQ )

Price: $89.10
Change: -2.36 (2.58%)
Volume: 786.2 K
4:00PM ET 12/01/2021
 

Read more news Recent News

Neurocrine Biosciences, Sosei Heptares Team Up to Develop Treatments for Schizophrenia, Other Neuropsychiatric Disorders
9:48AM ET 11/22/2021 MT Newswires

Neurocrine Biosciences (NBIX) and Sosei Group said Monday they signed a collaboration and licensing agreement to develop new compounds for the treatment of...

BMO Capital Starts Neurocrine Biosciences at Underperform With $76 Price Target
5:45AM ET 11/19/2021 MT Newswires

Neurocrine Biosciences (NBIX) has an average rating of outperform and price targets ranging from $76 to $150, according to analysts polled by Capital IQ....

JPMorgan Upgrades Neurocrine Biosciences to Overweight From Neutral; Price Target is $124
5:24AM ET 11/17/2021 MT Newswires

Neurocrine Biosciences (NBIX) has an average rating of outperform and price targets ranging from $100 to $150, according to analysts polled by Capital IQ....

Sector Update: Health Care Stocks Pare Gains Ahead of Close Tuesday
3:59PM ET 11/02/2021 MT Newswires

Health care stocks were well off their best levels of the day ahead of Tuesday's close, with the NYSE Health Care Index up 0.6% while the Health Care...

Company Profile

Business DescriptionNeurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA. View company web site for more details
Address12780 El Camino Real
San Diego, California 92130
Phone+1.858.617.7600
Number of Employees585
Recent SEC Filing12/01/20213
Chief Executive Officer & DirectorKevin Charles Gorman
Vice President-Information Technology & OperationsBill Wilson
Chief Financial OfficerMatthew C. Abernethy
Chief Research OfficerDimitri E. Grigoriadis

Company Highlights

Price Open$83.39
Previous Close$80.79
52 Week Range$79.89 - 120.27
Market Capitalization$7.7 B
Shares Outstanding94.9 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings19.03
Earnings per Share$4.83
Beta vs. S&P 500N/A
Revenue$451.2 M
Net Profit Margin41.59%
Return on Equity35.89%

Analyst Ratings as of 11/23/2021

Buy
15
Overweight
2
Hold
9
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset